CDK2 and ovarian cancer: In 2023, Yu et al. (Yu et al. 2023) reported the discovery of a highly potent and selective macrocyclic CDK2 inhibitor via generative models and structure‐based drug design that showed robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.